This Scientific Reports article evaluates a machine learning survival model trained on clinical and histological data. This model accurately identifies high-risk patients with hormone responsive HER2 negative breast cancer. It can help reduce the cost and time spent on more expensive genomic tests and assist medical professionals in the oncology field. Dr. Cognetti of Istituto Tumori Giovanni Paolo II is advocating for the machine learning model use.
Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?